NOTICE: This is an archived press release. Information contained on this page may be outdated. Please refer to our latest press releases for up-to-date information.

Post date: June 14 2004

Statement Regarding A Decision By Glaxosmithkline To Release Paxil Clinical Data

Attorney General Spitzer today issued the following statement in response to a decision by GlaxoSmithKline to release clinical data regarding the safety and effectiveness of its antidepressant drug Paxil. Spitzer sued the company on June 2 alleging that the company misled doctors about the drug.

"This is a positive first step toward changing a dangerous industry practice. We can no longer permit GSK and other pharmaceutical companies to selectively choose what research to make available to physicians and the public. It is unacceptable for companies like GSK to divulge favorable results while hiding negative data when the health of patients is at stake. While today's development by GSK does not resolve all of the issues in our litigation it does represent movement in the right direction."